Sun Pharma

  (Redirected from Sun Pharmaceutical)

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Sun Pharma has presence in more than 100 countries across the globe.[3] It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world,[4] with a total revenue of over US$4.5 billion as of June 2021.[5] The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.[4] Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.[6]

Sun Pharmaceutical Industries Limited
Founded1983; 38 years ago (1983)
FounderDilip Shanghvi
Area served
Key people
Dilip Shanghvi (CEO)
RevenueIncrease 334.73 billion (US$4.4 billion) (2020)[1]
Increase 50.10 billion (US$670 million) (2020)[1]
Increase 37.65 billion (US$500 million) (2020)[1]
Total assetsIncrease 682.52 billion (US$9.1 billion) (2020)[1]
Total equityIncrease 491.25 billion (US$6.5 billion) (2020)[1]
Number of employees
36,000 (2020)[1]
Footnotes / references


Sun Pharmaceuticals was founded by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five products to treat psychiatry ailments. Cardiology products were introduced in 1987[7] followed by gastroenterology products in 1989. Today it is ranked No.1 by prescriptions with 9 different classes of doctors in[8] India and a market leader in cardiology, gastroenterology, ortho, diabetology, dermatology, urology, and vitamins / minerals / nutrients.[9]

The 2014 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 4th[4] largest specialty generic company globally.

Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;[10] in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).[11]

Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.[12]

Sun Pharma requested USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs) belonging to its wholly owned subsidiary Ranbaxy Laboratories.[13]

Acquisitions and Joint VenturesEdit

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai, mainly for their extensive gynaecology and oncology brands. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.

In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company acquired a large stake in Taro Pharmaceuticals,[14] amongst the largest generic dermatology companies in the US, with operations across Canada and Israel. The company currently owns ~ 69% stake in Taro, for about $260 million.[15]

In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).[16]

In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals,[17] a dermatology device company; and generic pharma company URL Pharma [18] In 2013, the company announced an R&D joint venture for ophthalmology with the research company, Intrexon.[19]

On 6 April 2014, Sun Pharma acquired Ranbaxy in a US$4 billion landmark transaction to create the world’s 5th largest specialty generic pharmaceutical company.[20]

Then Sun Pharma entered into a licensing agreement with Merck & Co. Inc. for Tildrakizumab (MK- 3222) in order to further strengthen the specialty product pipeline.[21]

To access sterile injectable capacity in the US, it acquired Pharmalucence in the USA in the same year.[22]

In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.[23][24]

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.[24]

The following year Sun Pharma made some significant acquisitions, including 14 brands from Novartis in Japan to enter the Japanese market.[25]

It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.[4]

From 2016 to 2018, Sun Pharma launched some of its new products in the USA.[7] It launched its first branded ophthalmic product, BromSite™ in 2016.[26] In 2017, the company launched its speciality product Odomzo.[27] and then in 2018 another specialty product ILUMYA™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.[28]

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.[29] The company entered the Greater China market by partnering with China Medical System Holdings.[30] And it launched a speciality product Cequa in the United States for the treatment of dry eyes.[31]


In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSESPARC, BSE532872). In 2013, SPARC declared revenue of ₹873 million.[32] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update[33] of its pipeline (NDDS).[34]


Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list [35] in a study conducted by BlueBytes,[36] a leading Media Analytics firm in association with TRA Research,[37] a brand insights organization (both a part of the Comniscient Group).


1.Listed among the Forbes World’s Best Regarded companies"[5]

2. CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019[38]

3. Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum[39]


1. Listed among the Forbes World’s Best Employers 2020[40]

2. Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list[41]


  1. ^ a b c d e f "Sun Pharmaceutical Annual Report 2020" (PDF). Sun Pharmaceutical Limited. Retrieved 2 July 2019.
  2. ^ "Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results" (PDF). Sun Pharmaceutical. 4 February 2019. Retrieved 4 February 2019.
  3. ^ Banerjee, Avishek. "Sun Pharma: Global Is Local". BW Businessworld. Retrieved 6 August 2021.
  4. ^ a b c d "Sun Pharmaceuticals Industries Ltd". Business Standard India. Retrieved 6 August 2021.
  5. ^ a b "Sun Pharma Industries". Forbes. Retrieved 6 August 2021.
  6. ^ "Sun Pharma | IBEF". Retrieved 6 August 2021.
  7. ^ a b "Milestones & Recognitions | Sun Pharmaceutical Industries Limited". Sun Pharmaceutical Industries Ltd. Retrieved 6 August 2021.
  8. ^ "Strategic solutions", Hospitality Marketing, Routledge, pp. 210–219, 11 January 2013, ISBN 978-0-08-093848-6, retrieved 6 August 2021
  9. ^ Katja S, Ziegler (April 2019), "AWACS I (Ger)", Max Planck Encyclopedia of Comparative Constitutional Law, Oxford University Press, retrieved 6 August 2021
  10. ^ "US business remains Sun Pharma's weak spot". Retrieved 6 August 2021.
  11. ^ "Archived copy" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 10 April 2014.CS1 maint: archived copy as title (link)
  12. ^ "Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018". Focus on Surfactants. 2019 (3): 6. March 2019. doi:10.1016/j.fos.2019.03.069. ISSN 1351-4210.
  13. ^ "sun pharma announce withdraw anda". 20 December 2016. Retrieved 22 December 2016 – via economic times.
  14. ^ "USA – Taro Pharmaceutical Industries". Retrieved 19 July 2018.
  15. ^ "Corporate Website: Acquisitions". Archived from the original on 10 August 2011. Retrieved 19 July 2018.
  16. ^ "Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources". The Economic Times. Retrieved 6 August 2021.
  17. ^ "Sun Pharma to buy U.S.-based Dusa for $230 mln". Reuters India. Retrieved 2 July 2015.
  18. ^ Takeda Pharmaceutical Company Limited. "Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical". Retrieved 2 July 2015.
  19. ^ "Investors – Newsroom – Intrexon". Archived from the original on 10 April 2014. Retrieved 2 July 2015.
  20. ^ Reporter, B. S. (8 April 2014). "Sun Pharma buys Ranbaxy from Japan's Daiichi". Business Standard India. Retrieved 6 August 2021.
  21. ^ "Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab". The Economic Times. Retrieved 6 August 2021.
  22. ^ Unnikrishnan, C. H. (16 July 2014). "Sun Pharma acquires US injectables firm Pharmalucence". mint. Retrieved 6 August 2021.
  23. ^ "CCI clears Sun Pharma-Ranbaxy deal". Reuters India. Retrieved 2 July 2015.
  24. ^ a b "UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia". Reuters India. Retrieved 2 July 2015.
  25. ^ "Sun Pharma acquires Novartis brands in Japan for $293 million". @businessline. Retrieved 6 August 2021.
  26. ^ Monday; November 28; Tweet, 2016. "Sun Pharma Launches First Branded Ophthalmic Product in U.S." Retrieved 6 August 2021.CS1 maint: numeric names: authors list (link)
  27. ^ Trivedi, Isha (22 December 2016). "Sun Pharma to acquire Novartis's cancer drug Odomzo for $175 mn". mint. Retrieved 6 August 2021.
  28. ^ Medha (25 October 2018). "New drug launched for moderate-to-severe plaque psoriasis". Retrieved 6 August 2021.
  29. ^ "Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment-Business News , Firstpost". Firstpost. 27 November 2018. Retrieved 6 August 2021.
  30. ^ "Sun Pharma arm enters pact with China Medical System - ET HealthWorld". Retrieved 6 August 2021.
  31. ^ "Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US". Eyewire News. Retrieved 6 August 2021.
  32. ^ "Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts". Retrieved 2 July 2015.
  33. ^ "Archived copy" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 10 April 2014.CS1 maint: archived copy as title (link)
  34. ^ "SUN PHARMA ADVANCED RESEARCH COMPANY". Retrieved 2 July 2015.
  35. ^ "Archived copy". Archived from the original on 20 August 2016. Retrieved 18 August 2016.CS1 maint: archived copy as title (link)
  36. ^ "Blue Bytes". Retrieved 19 July 2018.
  37. ^ "TRA". Retrieved 19 July 2018.
  38. ^ "2019 Recipients". Mahatma Award. Retrieved 6 August 2021.
  39. ^ "ACEF-Asian Leaders Forum and Awards". Retrieved 6 August 2021.
  40. ^ "The World's Best Employers 2020". Forbes. Retrieved 6 August 2021.
  41. ^ "Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations | 28 comments". Retrieved 6 August 2021.

External linksEdit